News Image

NASDAQ:GMAB is showing good growth, while it is not too expensive.

By Mill Chart

Last update: Mar 21, 2024

Uncover the potential of GENMAB A/S -SP ADR (NASDAQ:GMAB), a growth stock that our stock screener found to be reasonably priced. NASDAQ:GMAB is excelling in growth aspects, maintaining a healthy financial position, and still offers an attractive valuation. We'll examine each aspect in detail.

Looking at the Growth

A key component of ChartMill's stock assessment is the Growth Rating, which spans from 0 to 10. This rating evaluates diverse growth factors, such as EPS and revenue growth, considering both past performance and future projections. NASDAQ:GMAB has received a 8 out of 10:

  • The Earnings Per Share has been growing by 22.70% on average over the past years. This is a very strong growth
  • The Revenue has grown by 12.87% in the past year. This is quite good.
  • Measured over the past years, GMAB shows a very strong growth in Revenue. The Revenue has been growing by 40.35% on average per year.
  • The Earnings Per Share is expected to grow by 31.70% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 18.76% on average over the next years. This is quite good.
  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.

Understanding NASDAQ:GMAB's Valuation Score

ChartMill assigns a proprietary Valuation Rating to each stock. The score is computed by evaluating various valuation aspects, like price to earnings and free cash flow, both absolutely as relative to the market and industry. NASDAQ:GMAB was assigned a score of 6 for valuation:

  • Based on the Price/Earnings ratio, GMAB is valued cheaply inside the industry as 95.42% of the companies are valued more expensively.
  • Based on the Price/Forward Earnings ratio, GMAB is valued cheaply inside the industry as 96.10% of the companies are valued more expensively.
  • GMAB's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. GMAB is cheaper than 95.93% of the companies in the same industry.
  • 97.12% of the companies in the same industry are more expensive than GMAB, based on the Price/Free Cash Flow ratio.
  • GMAB's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of GMAB may justify a higher PE ratio.
  • GMAB's earnings are expected to grow with 27.55% in the coming years. This may justify a more expensive valuation.

Unpacking NASDAQ:GMAB's Health Rating

Every stock is evaluated by ChartMill, receiving a Health Rating on a scale of 0 to 10. This assessment considers different health aspects, including liquidity and solvency, both in absolute terms and relative to industry peers. NASDAQ:GMAB has achieved a 8 out of 10:

  • An Altman-Z score of 24.31 indicates that GMAB is not in any danger for bankruptcy at the moment.
  • GMAB has a better Altman-Z score (24.31) than 92.88% of its industry peers.
  • GMAB has a debt to FCF ratio of 0.11. This is a very positive value and a sign of high solvency as it would only need 0.11 years to pay back of all of its debts.
  • GMAB has a Debt to FCF ratio of 0.11. This is amongst the best in the industry. GMAB outperforms 97.29% of its industry peers.
  • GMAB has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
  • A Current Ratio of 13.34 indicates that GMAB has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 13.34, GMAB belongs to the top of the industry, outperforming 85.76% of the companies in the same industry.
  • A Quick Ratio of 13.32 indicates that GMAB has no problem at all paying its short term obligations.
  • The Quick ratio of GMAB (13.32) is better than 85.76% of its industry peers.

Looking at the Profitability

Discover ChartMill's exclusive Profitability Rating, a proprietary metric that assesses stocks on a scale of 0 to 10. It takes into consideration various profitability ratios and margins, both in absolute terms and relative to industry peers. Notably, NASDAQ:GMAB has achieved a 7:

  • GMAB has a better Return On Assets (12.33%) than 97.63% of its industry peers.
  • GMAB has a better Return On Equity (13.77%) than 96.61% of its industry peers.
  • GMAB has a Return On Invested Capital of 12.63%. This is amongst the best in the industry. GMAB outperforms 96.95% of its industry peers.
  • The Profit Margin of GMAB (26.42%) is better than 98.14% of its industry peers.
  • GMAB's Operating Margin of 32.30% is amongst the best of the industry. GMAB outperforms 98.64% of its industry peers.
  • GMAB has a Gross Margin of 98.63%. This is amongst the best in the industry. GMAB outperforms 98.31% of its industry peers.

Our Affordable Growth screener lists more Affordable Growth stocks and is updated daily.

Our latest full fundamental report of GMAB contains the most current fundamental analsysis.

Keep in mind

This article should in no way be interpreted as advice in any way. The article is based on the observed metrics at the time of writing, but you should always make your own analysis and trade or invest at your own responsibility.

Back

GENMAB A/S -SP ADR

NASDAQ:GMAB (5/29/2024, 7:06:51 PM)

Premarket: 27.82 -0.17 (-0.61%)

27.99

-0.02 (-0.07%)

GMAB News

News Image7 days ago - Genmab A/SGenmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual Meeting
News Image9 days ago - Genmab A/SGenmab Completes Acquisition of ProfoundBio
News Image10 days ago - InvestorPlace7 Biotech Stocks That Could Breathe New Life Into Your Portfolio

Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions.

News Image13 days ago - Market News VideoJuly 19th Options Now Available For Genmab (GMAB)
News Image16 days ago - Genmab A/SGenmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) Congress
News Imagea month ago - InvestorPlaceGMAB Stock Earnings: Genmab Beats EPS, Beats Revenue for Q1 2024

GMAB stock results show that Genmab beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.

News Imagea month ago - Pfizer Inc.FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer
News Imagea month ago - Genmab A/STIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
News Imagea month ago - Investor's Business DailyWhy Big Pharma Is Following Novartis' Lead In A $25 Billion Market

The radiopharmaceuticals space could be worth up to $25 billion, according to one estimate.

News Image2 months ago - Investor's Business DailyGenmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBio

Genmab is buying a privately held company focused on antibody drug conjugates.

News Image2 months ago - Genmab A/SGenmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBio
GMAB Links
Follow us for more